Stephen Brannan, MD, Chief Medical Officer of Karuna Therapeutics, talks more on the phase II clinical data for KarXT, published in the New England Journal of Medicine.

Dr Brannan is chief medical officer at Karuna Therapeutics and a neuroscience drug development expert.

Receive trusted psychiatric news, expert analysis, and clinical insights — subscribe today to support your practice and your patients.

Subscribe Now!

Promising Publication: The Novel Schizophrenia Treatment Gaining Traction

Newsletter